To prevent further cases like this enzalutamide toxic myocarditis, we propose that genetic testing for the MR rs5522 polymorphism be performed before starting therapy with AR inhibitors in prostate cancer, particularly in high-risk patients or patients with comorbidities in organs known to be affected by drugs side effects. Here, AR is linked to prostate carcinoma.